Novo Nordisk (NVO)
Novo Nordisk (NVO)
One-line summary: The number-two GLP-1 franchise (Wegovy/Ozempic), tracked here as the relative loser leg opposite eli-lilly under the 2026 US drug-pricing (MFN/DTC) regime — NVO guided 2026 sales/profit down 5–13% on US price erosion and ex-US exclusivity loss while LLY sees revenue accelerating.
What it is
Novo Nordisk is the Danish pharma giant behind semaglutide (Ozempic/Wegovy). In this wiki it is the counterpart to LLY in the GLP-1 pricing/share chains — the name absorbing the downside of the most-favored-nation (MFN) and direct-to-consumer (DTC) pricing shift more than LLY.
Why it matters to stock-market
Under the 2026 US pricing regime (Medicare/Medicaid GLP-1 set at $245/month; Medicare obesity coverage live 1 July 2026 at $50 copay; TrumpRx DTC portal), price is falling but volume is expanding. The pair trade is LLY (winner, accelerating, oral orforglipron share edge) vs NVO (guided down). Goldman projects LLY's oral orforglipron at ~60% ($13.6B) of the 2030 oral share vs Novo's pill at 21%, with the duopoly holding ~85%.
Key facts
- 2026 guide down. NVO guided 2026 sales/profit down 5–13% on US price erosion and ex-US exclusivity loss, while LLY sees revenue accelerating. From 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026 (pharmaphorum).
- Losing the oral-share projection. Goldman: LLY orforglipron ~60% ($13.6B) of 2030 oral GLP-1 share vs NVO's pill at 21%; duopoly ~85% combined. From 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026.
- Prior wiki appearance (Catalent). Novo Holdings (NVO's controlling foundation-linked entity) took Catalent private for $16.5B, removing a top-3 independent CDMO from the merchant market — the capacity-tightening fact that feeds the biosecure-act-domestic-cdmo-reshoring / thermo-fisher chain.
Related
- eli-lilly — the pair-trade winner
- thermo-fisher — Novo Holdings' Catalent take-private tightens the CDMO capacity the TMO chain rests on
- 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026